Akeso‑Summit’s ivonescimab lands a prime ASCO plenary slot despite unclear survival data

The upcoming American Society of Clinical Oncology meeting will feature a plenary presentation from Akeso and Summit Therapeutics on their lung‑cancer candidate ivodescimab. Industry observers note that the slot is unusually prominent for a drug whose survival outcomes have not yet been disclosed.

Analysts are debating what the data might reveal, with some suggesting the results could be mixed while others hope for a positive signal. The lack of concrete information has fueled speculation across Wall Street and among biotech commentators.

Until the conference data are released, the market will likely remain cautious, watching closely for any indication of the drug’s efficacy and potential impact on the competitive landscape for lung‑cancer therapies.